SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Stride, Inc. (NYSE: LRN) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026. The firm urges investors who suffered substantial losses in LRN to contact Hagens Berman now to discuss their rights. The lawsuit seeks to recover investor losses sustained after the purported disclosure of two ...

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the "Class Period"), of the important January 20, 2026 lead plaintiff deadline. So what: If you purchased Jayud securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the prospects of its lead candidate, nimacimab, during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - The lawsuit claims that throughout the Class Period, the company misled investors about the potential success of nimacimab [2]. - Investors reportedly became aware of the misleading information on October 6, 2025, when Skye announced that nimacimab failed to meet its primary weight-loss endpoint in a Phase 2a trial, leading to a significant stock price drop of approximately 60%, closing at $1.90 [3]. Investor Information - Investors who purchased Skye securities during the Class Period have until January 16, 2026, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Coupang, Inc. and certain executive officers, alleging misleading statements and failure to disclose material adverse facts regarding the company's cybersecurity practices and the resulting risks to customer data [1][6]. Group 1: Lawsuit Details - The class action lawsuit was filed in the United States District Court for the Western District of Washington, expanding the class period to include all investors who purchased Coupang common stock from May 7, 2025, to December 16, 2025 [1][2]. - The lawsuit is titled Hakrae Lee, et al. v. Coupang, Inc., et al., and asserts claims under the Securities Exchange Act of 1934 [1]. Group 2: Company Overview - Coupang, based in Seattle, Washington, operates as a technology and commerce company, primarily through two segments: Product Commerce and Developing Offerings [4]. - The Product Commerce segment accounted for 88% of Coupang's total revenue in 2024, mainly through its South Korea-based subsidiary [4]. Group 3: Cybersecurity Concerns - The class action alleges that Coupang failed to maintain adequate cybersecurity measures, leading to significant risks of data breaches and unauthorized access to sensitive customer information [6]. - It was revealed that a security breach had already occurred in June 2025, which was not disclosed to investors [6]. Group 4: Impact of the Breach - On November 29, 2025, Coupang disclosed a cybersecurity incident affecting approximately 33.7 million customer accounts, resulting in a stock price drop of about 5.36% [7]. - Following the resignation of CEO Park Dae-joon on December 10, 2025, due to the data leak, Coupang's stock fell by approximately 3.2% [8]. - The full extent of the breach was acknowledged on December 16, 2025, leading to a further decline in stock price by about 2% [9].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Group 1: Bitdeer Technologies Group (NASDAQ: BTDR) - Class period is from June 6, 2024, to November 10, 2025, with a lead plaintiff deadline of February 2, 2026 [2] - Allegations include false and misleading statements regarding the SEAL04 chip's energy efficiency and its readiness for mass production, impacting the company's business outlook [2] Group 2: Gauzy Ltd. (NASDAQ: GAUZ) - Class period is from March 11, 2025, to November 13, 2025, with a lead plaintiff deadline of February 6, 2026 [3] - Allegations state that three French subsidiaries lacked financial means to meet debts, indicating potential insolvency and default risks, which misled investors about the company's financial health [3] Group 3: Integer Holdings Corporation (NYSE: ITGR) - Class period is from July 25, 2024, to October 22, 2025, with a lead plaintiff deadline of February 9, 2026 [4] - Allegations include overstating competitive position in the EP manufacturing market and mischaracterizing sales deterioration, leading to misleading statements about growth prospects [4] Group 4: F5, Inc. (NASDAQ: FFIV) - Class period is from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline of February 17, 2026 [5] - Allegations involve a significant security incident that jeopardized client security and the company's future, resulting in misleading statements about business operations [5]

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified class period, alleging that the company made false or misleading statements regarding its business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [3]. Allegations - The lawsuit claims that Telix overstated progress on its prostate cancer therapeutic candidates [3]. - It is alleged that the quality and performance of the company's supply chain and partners were exaggerated [3]. - As a result of these misrepresentations, statements regarding the company's business, operations, and prospects were deemed false or misleading [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the reality of falling demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60 per share, or over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, or more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. Investor Information - Investors are encouraged to seek additional information regarding their legal options and can submit their information to the law firm representing the class action [2][7].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales and Stock Performance - On May 5, 2025, BellRing disclosed that several key retailers reduced their inventory levels, which would negatively impact growth in Q3 2025. Following this announcement, the stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a stock price decline of $17.46, nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. - The company had previously claimed strong sales growth and market position for its electrophysiology devices, which is now being challenged [4]. Group 3: Financial Performance - Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025, following the announcement of lowered sales guidance [6]. - The company revised its 2025 sales guidance to a range of $1.840 billion to $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, citing slower adoption of two of its electrophysiology devices [6][5].